The financials
Syndax Pharmaceuticals, Inc. by the numbers
Syndax Pharmaceuticals, Inc. (SNDX) reported revenue of $65M in Q1 2026 (quarter ended March 31, 2026), up 224% from the same quarter a year earlier. That came with net loss of $43M. For the full year FY2025, revenue was $172M (+628% year on year) and net income −$285M.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $65M | $20M | +224% |
| Operating income | −$34M | −$84M | n/a |
| Net income | −$43M | −$85M | n/a |
| Diluted EPS | −$0.48 | −$0.98 | n/a |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $18.1M (+13%)
Collaboration grew +93% year on year
Segment Latestquarter on quarteryear on year
- Collaboration$18.1M$18.1MQoQ +13%year on year +93%+13%+93%
- Milestone--QoQ -year on year ---